Payment overview · 2025
General Payments
$374.88
8 reported records · 6 companies
Healthcare provider profile · identity verified
Laura Abels, DO
Allopathic & Osteopathic Physicians|Family Medicine · ANKENY, IA · NPI 1427313527
Verified facts
What the public records show
CMS Open Payments records show Laura Abels, DO received $374.88 in general payments during 2025 across 8 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $123.06 | 32.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $109.83 | 29.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $79.50 | 21.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.75 | 8.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 5.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.89 | 3.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $356.03 | 7 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $123.06 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $109.83 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $79.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.75 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.89 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 334 | 86 |
| Omeprazole | Omeprazole | 266 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 41 |
| Lisinopril | Lisinopril | 160 | 44 |
| Losartan Potassium | Losartan Potassium | 137 | 44 |
| Metformin Hcl | Metformin Hcl | 134 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 47 |
| Gabapentin | Gabapentin | 120 | 31 |
| Simvastatin | Simvastatin | 120 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 33 |
| Ozempic | Semaglutide | 103 | 18 |
| Sertraline Hcl | Sertraline Hcl | 100 | 22 |
| Trazodone Hcl | Trazodone Hcl | 98 | 19 |
| Potassium Chloride | Potassium Chloride | 89 | 17 |
| Tramadol Hcl | Tramadol Hcl | 83 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 21 |
| Furosemide | Furosemide | 78 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 21 |
| Meloxicam | Meloxicam | 58 | 16 |
| Famotidine | Famotidine | 57 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 11 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Allopurinol | Allopurinol | 51 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 11 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Glimepiride | Glimepiride | 47 | suppressed |
| Jardiance | Empagliflozin | 47 | 12 |
| Montelukast Sodium | Montelukast Sodium | 45 | 11 |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 11 |
| Atenolol | Atenolol | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | 11 |
| Alendronate Sodium | Alendronate Sodium | 37 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Carvedilol | Carvedilol | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $374.88 · 8 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, DUPIXENT, JARDIANCE, QULIPTA, REXULTI, UBRELVY, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error